Objective: To investigate the clinical efficacy of high-intensity focused ultrasound ablation (HIFU) in treating fibroadenomas of different breast tissue types.
Methods: A retrospective analysis was conducted on 201 patients diagnosed with breast fibroadenoma via core needle biopsy between January 2024 and November 2024, involving a total of 314 lesions. Patients were categorized into fatty, loose, mixed, and dense groups based on the American College of Radiology (ACR) breast composition classification. Baseline characteristics, lesion features of fibroadenomas, HIFU treatment parameters, follow-up duration, and tumor volume reduction rate (VRR) were recorded and comparatively analyzed.
Results: The average surgical power in the loose group (142.8±38.5 W) was significantly higher than that in the fatty group (128.7±23.3 W), mixed group (128.8±36.6 W), and dense group (121.4±39.5 W), with statistically significant differences (p<0.05). The post-HIFU treatment average VRRs for the fatty, loose, mixed, and dense groups were 72.9±16%, 61.6±24%, 55%±22%, and 49%±32%, respectively. LSD-t test analysis revealed statistically significant differences between pairwise comparisons, including fatty versus loose, fatty versus mixed, fatty versus dense, and loose versus dense groups (p<0.05).
Conclusion: HIFU is a safe and effective treatment for fibroadenomas across different breast tissue types, with the highest surgical power required in the loose tissue subtype. Volume reduction rates varied among glandular classifications, demonstrating superior outcomes in the fat-rich subtype.
If you have any questions about submitting your review, please email us at [email protected].